BCL2L1 and cancer: Moreover, it seemed that this combined liposomal therapy did not induce the settlement of cancer cell resistance to anti-angiogenic drugs, as treated tumors showed 1.5‐fold increase of the Bax/Bcl-xL production ratio (Fig. 4E, P < 0.05) and presented several morphological hallmarks of apoptosis (Supplementary Figure 4D).